Grifols Sa Adr Stock Current Asset
GIKLY Stock | USD 4.52 0.05 1.12% |
Grifols SA ADR fundamentals help investors to digest information that contributes to Grifols SA's financial success or failures. It also enables traders to predict the movement of Grifols Pink Sheet. The fundamental analysis module provides a way to measure Grifols SA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Grifols SA pink sheet.
Grifols |
Grifols Current Asset Analysis
Grifols SA's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Grifols SA Current Asset | 2.95 B |
Most of Grifols SA's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Grifols SA ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
Competition |
In accordance with the recently published financial statements, Grifols SA ADR has a Current Asset of 2.95 B. This is 37.23% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The current asset for all United States stocks is 68.38% higher than that of the company.
Grifols Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Grifols SA's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Grifols SA could also be used in its relative valuation, which is a method of valuing Grifols SA by comparing valuation metrics of similar companies.Grifols SA is currently under evaluation in current asset category among related companies.
Grifols Fundamentals
Return On Equity | 0.0182 | |||
Return On Asset | 0.0155 | |||
Profit Margin | 0.01 % | |||
Operating Margin | 0.09 % | |||
Current Valuation | 16.07 B | |||
Shares Outstanding | 1.36 B | |||
Shares Owned By Institutions | 0.02 % | |||
Price To Earning | 9.31 X | |||
Price To Book | 1.03 X | |||
Price To Sales | 1.47 X | |||
Revenue | 4.93 B | |||
Gross Profit | 1.96 B | |||
EBITDA | 861.51 M | |||
Net Income | 182.8 M | |||
Cash And Equivalents | 549.09 M | |||
Cash Per Share | 0.40 X | |||
Total Debt | 6.1 B | |||
Debt To Equity | 1.14 % | |||
Current Ratio | 2.68 X | |||
Book Value Per Share | 4.66 X | |||
Cash Flow From Operations | 596.98 M | |||
Earnings Per Share | 0.05 X | |||
Price To Earnings To Growth | 0.53 X | |||
Target Price | 55.5 | |||
Number Of Employees | 27.58 K | |||
Beta | 0.48 | |||
Market Capitalization | 9.97 B | |||
Total Asset | 19.23 B | |||
Retained Earnings | 468 M | |||
Working Capital | 2.03 B | |||
Current Asset | 2.95 B | |||
Current Liabilities | 926 M | |||
Z Score | 0.6 | |||
Annual Yield | 0.03 % | |||
Five Year Return | 1.50 % | |||
Net Asset | 19.23 B |
About Grifols SA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Grifols SA ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Grifols SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Grifols SA ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company was founded in 1940 and is headquartered in Barcelona, Spain. Grifols Sa operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 27584 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Grifols SA Piotroski F Score and Grifols SA Altman Z Score analysis. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Grifols Pink Sheet analysis
When running Grifols SA's price analysis, check to measure Grifols SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Grifols SA is operating at the current time. Most of Grifols SA's value examination focuses on studying past and present price action to predict the probability of Grifols SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Grifols SA's price. Additionally, you may evaluate how the addition of Grifols SA to your portfolios can decrease your overall portfolio volatility.
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
FinTech Suite Use AI to screen and filter profitable investment opportunities |